


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently amended) A pharmaceutical composition for preventing or treating viral infectious diseases comprising a compound represented by the following general formula (I):



[[I]] wherein

A represents a phenyl group substituted with -OX, or a 3-indolyl group;

X represents a hydrogen atom, a linear or branched alkyl group having 1 to 8 carbon atoms, a linear or branched alkenyl group having 2 to 8 carbon atoms, or a linear or branched alkynyl group having 2 to 8 carbon atoms;

B represents a hydrogen atom, a hydroxyl group, an oxo group, -N(R⁴)(R⁵), =N-OH, =N-OR⁶ or a halogen atom;

R⁴ and R⁵ may be the same or different, and each represent a hydrogen atom, a linear or branched alkyl group having 1 to 6 carbon atoms, a linear or branched alkenyl group having 2 to 6 carbon atoms, or a linear or branched alkynyl group having 2 to 6 carbon atoms, or R⁴ and R⁵ together represent a 3 to 8 membered ring;

R⁶ represents a linear or branched alkyl group having 1 to 8 carbon atoms (which may be substituted with an amino group which may be mono- or di-substituted with a linear or branched alkyl group having 1 to 4 carbon atoms);

D represents a hydrogen atom or a hydroxyl group; bond E represents a single bond or double bond; R¹, R² and R³ may be the same or different, and each represent a hydrogen


atom, a hydroxyl group, an amino group (which may be mono- or di-substituted with a linear or branched alkyl group having 1 to 4 carbon atoms), -OZ, a linear or branched alkyl group having 1 to 4 carbon atoms, a linear or branched alkenyl group having 2 to 4 carbon atoms, or a linear or branched alkynyl group having 2 to 4 carbon atoms; and,

Z represents a linear or branched alkyl group having 1 to 4 carbon atoms, a linear or branched alkenyl group having 2 to 4 carbon atoms, or a linear or branched alkynyl group having 2 to 4 carbon atoms[D] ;

a prodrug thereof or a pharmaceutically acceptable salt thereof.

2. **(Currently amended)** The pharmaceutical composition according to claim 1

comprising the compound of formula (I) according to claim 1 represented by the following general formula (I'), a prodrug thereof or a pharmaceutically acceptable salt thereof:



[[I]] wherein A, B, D, bond E, R¹, R² and R³ are the same as defined in claim 1 [D]].

3. **(Previously presented)** The pharmaceutical composition according to claim 1 comprising a compound of formula (I), a prodrug thereof or a pharmaceutically acceptable salt thereof wherein A represents a phenyl group substituted with -OX at position 4, X represents a hydrogen atom, a linear or branched alkyl group having 1 to 8 carbon atoms, a linear or branched alkenyl group having 2 to 8 carbon atoms, or a linear or branched alkynyl group having 2 to 8 carbon atoms.

4. **(Previously presented)** The pharmaceutical composition according to claim 1 comprising a compound of formula (I), a prodrug thereof or a pharmaceutically acceptable salt thereof, wherein B represents an oxo group, a hydrogen atom, a hydroxyl group or =N-OR⁶.

5. **(Previously presented)** The pharmaceutical composition according to claim 1 comprising a compound of formula (I), a prodrug thereof or a pharmaceutically acceptable salt thereof, wherein R¹, R² and R³ may be the same or different and each represent a hydroxyl group, an amino group, or -OZ (wherein Z represents a linear or branched alkyl group having 1 to 4 carbon atoms).


6. **(Previously presented)** The pharmaceutical composition according to claim 1 comprising a compound of formula (I), a prodrug thereof or a pharmaceutically acceptable salt thereof, wherein A represents a phenyl group substituted with -OX at position 4, X represents a hydrogen atom, a linear or branched alkyl group having 1 to 8 carbon atoms, a linear or branched alkenyl group having 2 to 8 carbon atoms or a linear or branched alkynyl group having 2 to 8 carbon atoms, B represents an oxo group, a hydroxyl group or =N-OR⁶, and R¹, R² and R³ may be the same or different and each represent a hydroxyl group or -OZ (wherein Z represents a linear or branched alkyl group having 1 to 4 carbon atoms).

7. **(Original)** The pharmaceutical composition according to claim 6 comprising a compound of formula (I), a prodrug thereof or a pharmaceutically acceptable salt thereof, wherein X represents a linear or branched alkyl group having 1 to 8 carbon atoms, a linear or branched alkenyl group having 2 to 8 carbon atoms or a linear or branched alkynyl group having 2 to 8 carbon atoms, B represents an oxo group or a hydroxyl group, and R¹, R² and R³ each represent a hydroxyl group.


8. **(Previously presented)** The pharmaceutical composition according to claim 1 comprising a compound of formula (I), a prodrug thereof or a pharmaceutically acceptable salt thereof, wherein A represents a 3-indolyl group.

9. **(Original)** The pharmaceutical composition according to claim 8 comprising a compound of formula (I), a prodrug thereof or a pharmaceutically acceptable salt thereof, wherein B represents an oxo group or a hydroxyl group, and R^1 , R^2 and R^3 each represent a hydroxyl group.


10. **(Currently Amended)** The pharmaceutical composition according to claim 1 comprising a compound of formula (I), a prodrug thereof of a pharmaceutically acceptable salt thereof, selected from the compounds indicated below: [[.]]




No.1




No.2




No.3




No.4




No.5




No.6




No.7




No.8




No.9




No.10




No.11



No.12




No.13




No.14


or




No.15




21




22



23




24




25

or




26


11. **(Currently Amended)** The pharmaceutical composition according to claim 1 comprising a compound of formula (I), a prodrug thereof or a pharmaceutically acceptable salt thereof, selected from the compounds indicated below: [[.]].




No.1




No.2




No.3




No.5




No.6




No.7




No.8



No.9




No.12




No.14


or




No.15




21




22



23




24






25

or




12. **(Currently amended)** The pharmaceutical composition according to claim 1 comprising a compound of formula (I), a prodrug thereof or a pharmaceutically acceptable salt thereof, selected from the compounds indicated below : [[.]]





No.7

or




No.8

13. **(Previously presented)** The pharmaceutical composition according to claim 1, wherein the viral infectious disease is HCV infection.

14. **(Original)** The pharmaceutical composition according to claim 13, wherein the HCV infection is hepatitis C.

15. **(Currently amended)** A compound represented by the following general formula (I):



[[I]] wherein

A represents a phenyl group substituted with -OX;

X represents a hydrogen atom, a linear or branched alkyl group having 1 to 8 carbon atoms, a linear or branched alkenyl group having 2 to 8 carbon atoms, or a linear or branched alkynyl group having 2 to 8 carbon atoms;

B represents a hydrogen atom, a hydroxyl group, an oxo group, -N(R⁴)(R⁵), =N-OH, =N-OR⁶ or a halogen atom;

R⁴ and R⁵ may be the same or different, and each represent a hydrogen atom, a linear or branched alkyl group having 1 to 6 carbon atoms, a linear or branched alkenyl group having 2 to 6 carbon atoms, or a linear or branched alkynyl group having 2 to 6 carbon atoms, or R⁴ and R⁵ together represent a 3 to 8 membered ring;


R⁶ represents a linear or branched alkyl group having 1 to 8 carbon atoms (which may be substituted with an amino group which may be mono- or di-substituted with a linear or branched alkyl group having 1 to 4 carbon atoms [[D]]);

D represents a hydrogen atom or a hydroxyl group; bond E represents a single bond or double bond;

R¹, R² and R³ may be the same or different, and each represent a hydrogen atom, a hydroxyl group, an amino group (which may be mono- or di-substituted with a linear or branched alkyl group having 1 to 4 carbon atoms), -OZ, a linear or branched alkyl group having 1 to 4 carbon atoms, a linear or branched alkenyl group having 2 to 4 carbon atoms, or a linear or branched alkynyl group having 2 to 4 carbon atoms; and,

Z represents a linear or branched alkyl group having 1 to 4 carbon atoms, a linear or branched alkenyl group having 2 to 4 carbon atoms, or a linear or branched alkynyl group having 2 to 4 carbon atoms, with the proviso that the case in which A is a phenyl group substituted with -OX at the p position, X is a 2-isopentenyl group or a hydrogen atom, B is an oxo group, D is a hydrogen atom, E represents a double bond, and all of R¹ to R³ are a hydroxyl group, and the case in which A is a phenyl group substituted with -OX at position p, X is a 2-isopentenyl group, B is an oxo group, D is a hydrogen atom, bond E represents a double bond, and all of R¹ to R³ are a methoxy group are excluded)
a prodrug thereof or a pharmaceutically acceptable salt thereof.

16. **(Currently amended)** A compound represented by the following general formula (I):



[(I)] wherein

A represents a phenyl group substituted with -OX;

X represents a hydrogen atom, a linear or branched alkyl group having 1 to 8 carbon atoms, a linear or branched alkenyl group having 2 to 8 carbon atoms, or a linear or branched alkynyl group having 2 to 8 carbon atoms;

B represents a hydrogen atom, a hydroxyl group, an oxo group, -N(R⁴)(R⁵), =N-OH, =N-OR⁶ or a halogen atom;

R⁴ and R⁵ may be the same or different, and each represent a hydrogen atom, a linear or branched alkyl group having 1 to 6 carbon atoms, a linear or branched alkenyl group having 2 to 6 carbon atoms, or a linear or branched alkynyl group having 2 to 6 carbon atoms, or R⁴ and R⁵ together represent a 3 to 8 membered ring;


R⁶ represents a linear or branched alkyl group having 1 to 8 carbon atoms (which may be substituted with an amino group which may be mono- or di-substituted with a linear or branched alkyl group having 1 to 4 carbon atoms [(D)]);

D represents a hydrogen atom or a hydroxyl group; bond E represents a single bond or double bond;

R¹, R² and R³ may be the same or different, and each represent a hydrogen atom, a hydroxyl group, an amino group (which may be mono- or di-substituted with a linear or branched alkyl group having 1 to 4 carbon atoms), -OZ, a linear or branched alkyl group having 1 to 4 carbon atoms, a linear or branched alkenyl group having 2 to 4 carbon atoms, or a linear or branched alkynyl group having 2 to 4 carbon atoms; and,

Z represents a linear or branched alkyl group having 1 to 4 carbon atoms, a linear or branched alkenyl group having 2 to 4 carbon atoms, or a linear or branched alkynyl group having 2 to 4 carbon atoms, with the proviso that the case in which A is a phenyl group substituted with -OX at position p and X is a hydrogen atom, and the case in which A is a phenyl group substituted with -OX at position p, X is a 2-isopentenyl group, B is an oxo group, D is a hydrogen atom, bond E indicates a double bond, and all of R¹ to R³ are a hydroxyl group or a methoxy group are excluded);
a prodrug thereof or a pharmaceutically acceptable salt thereof.


17. **(Currently amended)** The compound of formula (I) according to claim 15 or 16 represented by the following general formula (I'), a prodrug thereof or a pharmaceutically acceptable salt thereof:




[[I]] wherein A, B, D, bond E, R¹, R² and R³ are the same as described in claim 15 [D]].

18. **(Previously presented)** The compound of formula (I) according to claim 15, a prodrug thereof or a pharmaceutically acceptable salt thereof, wherein X represents a linear or branched alkyl group having 1 to 8 carbon atoms, a linear or branched alkenyl group having 2 to 8 carbon atoms or a linear or branched alkynyl group having 2 to 8 carbon atoms, and B represents a hydroxyl group, an oxo group or =N-OR⁶.


19. **(Currently Amended)** The compound of formula (I) according to claim 15 represented by the following ~~formula, a prodrug formulas, prodrugs~~ thereof or a pharmaceutically acceptable ~~salt salts~~ thereof : [[.]]




No.4




No.6




No.8




No.10




No.11



No.12




No.13





No.14


or




No.15



or




20. **(Currently Amended)** The compound of formula (I) according to claim 15 represented by the following formula, ~~a prodrug formulas, prodrugs thereof~~ or a pharmaceutically acceptable salt ~~salts thereof~~ : ~~[[.]]~~




No.6


or



No.8




21



22

or



21. **(Previously presented)** A pharmaceutical composition comprising a compound of formula (I) according to claim 15, a prodrug thereof or a pharmaceutically acceptable salt thereof.

22. **(Original)** The pharmaceutical composition according to claim 21 for preventing or treating of viral infectious diseases.

23. **(Original)** The pharmaceutical composition according to claim 22, wherein the viral infectious disease is HCV infection.

24. **(Original)** The pharmaceutical composition according to claim 23, wherein the HCV infection is hepatitis C.